Forbion Growth Opportunities Fund I Cooperatief U.A. is an investment firm that reports beneficial ownership of shares in enGene Therapeutics Inc. (ENGN) under U.S. securities law. It has submitted 2 SEC insider filings since 2024, most recently in November 2024.
Every role Forbion Growth Opportunities Fund I Cooperatief U.A. has reported on a Form 4, reconstructed from the filings themselves. Reporting insiders must state their relationship to the issuer (officer title, director seat, or 10% ownership) on every filing.
enGene Therapeutics Inc. (ENGN)2 filingsUpdated Aug 30, 2026
Forbion Growth Opportunities Fund I Cooperatief U.A. files SEC Form 4 reports at enGene Therapeutics Inc. (ENGN). 2 SEC Form 4 filings on record, most recently on 1 November 2024. Most recent open-market trade: bought $5.00M of ENGN on 1 November 2024. Lifetime open-market purchases: $8.01M. Historical track record: 4/5 stars across 14 tracked purchases.
Every recent SEC Form 4 transaction Forbion Growth Opportunities Fund I Cooperatief U.A. has reported, most recent first.
InsiderAlpha computes a forward-return-based score for every insider with enough Form 4 purchase history. The metrics below reflect realized performance after each tracked open-market purchase.
| Metric | Value |
|---|---|
| InsiderAlpha rating | ★★★★☆ (4/5) |
| Total purchases tracked | 14 |
| Purchases with forward-return data | 14 |
| 30-day win rate | 71% |
| 90-day win rate | 93% |
| Avg 5-day return | +6.75% |
| Avg 30-day return | +20.39% |
| Avg 90-day return | +32.10% |
| Best 30-day return |
InsiderAlpha's records for Forbion Growth Opportunities Fund I Cooperatief U.A. go back to 2024: 2 primary Form 4 filings, an average of 0.7 per year. The typical open-market purchase is $572K (14 buys totaling $8.01M). The largest single buy on record is $5.00M of ENGN in 2024. No transaction on record carries a Rule 10b5-1 flag - the filings look discretionary rather than pre-scheduled, which makes their timing more informative as a signal.
Insiders who have reported open-market trades at the same companies as Forbion Growth Opportunities Fund I Cooperatief U.A.. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
Forbion Growth Opportunities Fund I Cooperatief U.A. is an investment firm of enGene Therapeutics Inc. (ENGN). InsiderAlpha holds 2 primary Form 4 filings for it, the earliest from 2024, updated as new SEC EDGAR filings are processed.
The most recent primary Form 4 on record is dated 1 November 2024, one of 2 filings going back to 2024.
Recorded transactions: 14 open-market purchases ($8.01M) and 0 open-market sales across all tracked filings.
Across 14 tracked purchases, Forbion Growth Opportunities Fund I Cooperatief U.A. averaged +20.4% avg 30-day return with a 71% 30-day win rate. InsiderAlpha rates the track record at 4/5 stars.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
A free account opens the full scored daily plan and every past day, a watchlist for any ticker, and 3 months of price history on every company page. No card.
Free plan available · Paid plans start with a 7-day free trial
$ENGN enGene Therapeutics Inc.11.8K shares @ $6.55$78K
| +46.12% |